ADMA Biologics Reports FDA Compliance Status for its Manufacturing Facility has Improved FDA Inspection Database Confirms VAI Status of Boca Raton, FL Facility RI-002's Biologics License Application ("BLA") Resubmission

ADMA Biologics Reports FDA Compliance

Status for its Manufacturing Facility has Improved

FDA Inspection Database Confirms VAI

Status of Boca Raton, FL Facility

RI-002's Biologics License Application ("BLA") Resubmission Targeted for

RAMSEY, N.J. and BOCA RATON, FL., - September 5, 2018

- ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a vertically integrated commercial

biopharmaceutical company that manufactures, markets and develops specialty plasma-based biologics for the prevention and treatment

of certain infectious diseases, announces that the United States Food and Drug Administration ("FDA") inspection database

classification website has been updated and confirms ADMA's compliance status has improved to Voluntary Action Indicated

"We are pleased that the FDA has acknowledged the improved

current good manufacturing practice ("cGMP") conditions at our manufacturing facility and updated its database accordingly,"

stated Adam Grossman, President and Chief Executive Officer of ADMA Biologics, Inc. "We are excited to finally be in a position

to resubmit our Biologics License Application ("BLA") for RI-002 during the third quarter of 2018, which we believe

is a needed Intravenous Immune Globulin ("IVIG") option for patients who suffer with Primary Humoral Immunodeficiency

Disease ("PIDD"). We will announce related information pertaining to RI-002's BLA filing when the Company receives

correspondence from FDA."

ADMA Biologics, Inc. (ADMA)

ADMA Biologics is a vertically integrated commercial biopharmaceutical company that manufactures, markets and develops specialty

plasma-based biologics for the treatment of Primary Immune Deficiency Disease ("PIDD") and the prevention and treatment

of certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted

to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include

immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for other

medical reasons. ADMA has received U.S. Patents 9,107,906, 9,714,283, 9,815,886 and 9,969,793 related to certain aspects of its

lead product candidate, RI-002. For more information, please visit www.admabiologics.com.

ADMA's lead portfolio product candidate, RI-002, which has demonstrated positive Phase III pivotal clinical trial data, is a specialty

plasma-derived, polyclonal, intravenous immune globulin ("IVIG") derived from human plasma containing naturally occurring

polyclonal antibodies (e.g., Streptococcus pneumoniae, H. influenza type B, cytomegalovirus ("CMV"), measles, tetanus,

etc.) as well as plasma from donors tested to have high levels of neutralizing antibodies to respiratory syncytial virus ("RSV").

ADMA is pursuing an indication for the use of this specialty IVIG product for treatment of patients diagnosed with PIDD. Polyclonal

antibodies are the primary active component of IVIG products. Polyclonal antibodies are proteins that are used by the body's immune

system to neutralize microbes, such as bacteria and viruses and prevent against infection and disease. Data review which has been

published in peer reviewed journals indicates that the polyclonal antibodies present in RI-002 support its ability to prevent

infections in immune-compromised patients. This data and other information about RI-002 or ADMA Biologics products can be found

on the Company website at: www.admabiologics.com/therapies and www.admabiologics.com. RI-002 is protected by U.S. Patents: 9,107,906,

9,714,283, 9,815,886 and 9,969,793, the latter of which affords the Company patent exclusivity for the use of an immune globulin

as a prevention and/or treatment for any type of respiratory infection.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements"

pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. ("we",

"our" or the "Company"). Forward-looking statements include, without limitation, any statement that may

predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate,"

"project," "intend," "forecast," "target," "anticipate," "plan,"

"planning," "expect," "believe," "will," "is likely," "will likely,"

"should," "could," "would," "may," or, in each case, their negative, or words or expressions

of similar meaning. These forward-looking statements also include, but are not limited to, statements concerning our plans to

develop, manufacture, market, launch and expand our own commercial infrastructure and commercialize our current products and future

products, the safety, efficacy and expected timing of, and our ability to, obtain and maintain regulatory approvals of our current

products and product candidates, and the labeling or nature of any such approvals, the success of our work with our third party

vendors and the U.S. Food and Drug Administration (the "FDA") in furtherance of and progress towards an approval of

our Biologics License Application for specialty plasma-based biologics and the ability of such third parties to respond adequately

or in a timely manner to the issues raised by the FDA, our ability to successfully pursue commercialization and prelaunch activities,

the timeframe within which we may receive approval from the FDA for specialty plasma-based biologics, if at all, the potential

of our specialty plasma-based biologics to provide meaningful clinical improvement for patients living with Primary Immune Deficiency

Disease or other indications, our ability to realize increased prices for plasma growth in the plasma collection industry and

our expectations for future capital requirements. Actual events or results may differ materially from those described in this

document due to a number of important factors. Current and prospective security holders are cautioned that there also can be no

assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant

uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded

as a representation or warranty by ADMA or any other person that the objectives and plans of ADMA will be achieved in any specified

time frame, if at all. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update

any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are

subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events,

to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited

to, the risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most

recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.

Executive Vice President and Chief Financial Officer

|201-478-5552 | www.admabiologics.com

INVESTOR RELATIONS CONTACT:

Managing Director, LifeSci Advisors, LLC | 212-915-2568